Page 5 - எங்களுக்கு ஒழுங்குமுறை அதிகாரம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Die Grossmutter, die J P Morgan und ihre Enkel verklagt
finews.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finews.ch Daily Mail and Mail on Sunday newspapers.
Rocket Internet: Berliner Investor bringt SPAC an den Start
deraktionaer.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from deraktionaer.de Daily Mail and Mail on Sunday newspapers.
Amazon: Millionen-Strafe, Chefwechsel & starke Zahlen! Die Aktie zieht an
boersennews.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boersennews.de Daily Mail and Mail on Sunday newspapers.
SpaceX Starlink bringt erste Satelliten mit Laser-Links in Stellung
heise.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from heise.de Daily Mail and Mail on Sunday newspapers.
Share:
PARIS and NEW YORK, Jan. 18, 2021 (GLOBE NEWSWIRE)
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure today announced the launch of its Phase III REFRESH study in difficult-to-treat
(
(2) hypertension.
This new study is part of firibastat s Phase III clinical development and aims to assess long-term safety as well as the three-month efficacy after a single daily dose of firibastat 1000mg in treatment resistant hypertensive patients. We are thrilled to launch this new pivotal study as a precursor to potential market approval of single dose firibastat, which we believe to be the best regimen for chronic treatment of resistant of difficult-to-treat hypertension, said Jean-Philippe Milon, Chief Executive Officer at Quantum Genomics.